Results 31 to 40 of about 79,696 (205)
Cardiac Uses of Phosphodiesterase-5 Inhibitors
Journal of the American College of Cardiology, 2012 Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability in the penis and its supplying vasculature, resulting in vasodilation and increased blood flow. PDE5Is might benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the body, including the pulmonary and systemic ...
Schwartz, Bryan G. +4 more
openaire +2 more sources
Is phosphodiesterase type 5 inhibitor use associated with condom breakage? [PDF]
, 2009 This is an open access article - Copyright © 2009 by the BMJ Publishing Group Ltd. All rights reserved.We tested the hypothesis that phosphodiesterase type 5 inhibitor (PDE5i) use would be associated with increased likelihood of condom breakage using an
Crosby, RA +3 more
core +1 more source
5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6- (3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one [PDF]
, 2018 Natural and semi-synthetic compounds are being studied as novel phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction, pulmonary hypertension, and lower urinary symptoms.
Ongaro, Alberto +2 more
core +1 more source
Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line [PDF]
, 2017 Phosphodiesterase 5A (PDE5A) specifically degrades the ubiquitous second messenger cGMP and experimental and clinical data highlight its important role in cardiac diseases.
Barbagallo, Federica +13 more
core +1 more source
cAMP-Inhibits Cytoplasmic Phospholipase A(2) and Protects Neurons against Amyloid-beta-Induced Synapse Damage [PDF]
, 2015 A key event in Alzheimer’s disease (AD) is the production of amyloid-β (Aβ) peptides and the loss of synapses. In cultured neurons Aβ triggered synapse damage as measured by the loss of synaptic proteins. α-synuclein (αSN), aggregates of which accumulate
Bate, C, Williams, A
core +2 more sources
Antioxidant effects of phosphodiesterase-5 inhibitors [PDF]
Cardiovascular Research, 2013 This letter refers to ‘The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension’ by Y.-F. Fan et al ., Cardiovascular Research (2013) 99, 395–403. Fan et al .1 have shown convincing results indicating that the phosphodiesterase-5 (PDE5) inhibitor vardenafil reduces oxidative stress and this
openaire +2 more sources
Pharmacotherapy of erectile dysfunction: Current standards
Indian Journal of Urology, 2006 Pharmacotherapy is currently the therapeutic option of choice for erectile dysfunction. Comprising mainly intracavernosal injection therapy using alprostadil or alprostadil combined with phentolamine and/or papaverine and oral phosphodiesterase-5 ...
Kew-Kim Chew
doaj +1 more source
Applied Sciences, 2021 Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the to onset and progression of the disease.
Giovanni Ribaudo +2 more
doaj +1 more source
Use of the KlADH3 promoter for the quantitative production of the murine PDE5A isoforms in the yeast Kluyveromyces lactis [PDF]
, 2017 Background: Phosphodiesterases (PDE) are a superfamily of enzymes that hydrolyse cyclic nucleotides (cAMP/ cGMP), signal molecules in transduction pathways regulating crucial aspects of cell life.
Biagioni, Stefano +5 more
core +1 more source